Cargando…

Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin

It has been reported that the 9‐aminoanthracycline amrubicin shows good efficacy in human tumor xenograft models. We studied the disposition and metabolism of amrubicin in mice, in comparison with those of doxorubicin. Amrubicinol, a 13‐hydroxy metabolite of amrubicin, which is 10 to 100 times more...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguchi, Toshihiro, Ichii, Shinji, Morisada, Shinya, Yamaoka, Takashi, Yanagi, Yoshikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1998
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921696/ https://www.ncbi.nlm.nih.gov/pubmed/9849586 http://dx.doi.org/10.1111/j.1349-7006.1998.tb00497.x

Ejemplares similares

Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells
por: Yamaoka, Takashi, et al.
Publicado: (1998)

In vivo Efficacy and Tumor‐selective Metabolism of Amrubicin to Its Active Metabolite
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

Uptake and Intracellular Distribution of Amrubicin, a Novel 9‐Amino‐anthracycline, and Its Active Metabolite Amrubicinol in P388 Murine Leukemia Cells
por: Yamaoka, Takashi, et al.
Publicado: (1999)

Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts
por: Morisada, Shinya, et al.
Publicado: (1989)

Toxicological Aspects of a Novel 9‐Aminoanthracycline, SM‐5887
por: Morisada, Shinya, et al.
Publicado: (1989)

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex
por: Hanada, Mitsuharu, et al.
Publicado: (1998)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma
por: Sakaida, Emiko, et al.
Publicado: (2017)

Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023)

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
por: Yamamoto, Michiko, et al.
Publicado: (2009)

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver
por: Isobe, Taichi, et al.
Publicado: (2009)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study
por: Sone, Hideyuki, et al.
Publicado: (2018)

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
por: Horita, Nobuyuki, et al.
Publicado: (2016)

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

Incremental low doses of amrubicin for the treatment of bone marrow metastasis in small cell lung cancer
por: Asai, Nobuhiro, et al.
Publicado: (2013)

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
por: Sekine, Ikuo, et al.
Publicado: (2016)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
por: Uda, Sayaka, et al.
Publicado: (2022)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2019)

The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis
por: Wu, Ji-Feng, et al.
Publicado: (2019)

Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report
por: Maesaka, Fumisato, et al.
Publicado: (2019)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis
por: Hanada, Mitsuharu, et al.
Publicado: (2008)

C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin
por: Nagata, Misato, et al.
Publicado: (2013)

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2020)

Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer: A protocol of systematic review and meta-analysis
por: Dang, Dong, et al.
Publicado: (2020)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k0l5nlcdd76mpbs29c6g9eb9rd